High-frequency magnetic stimulation effects on brain blood flow in small vessel disease patients

Effects of High-frequency Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Cerebral Small Vessel Disease

This study tests if a special brain stimulation technique can improve blood flow and help people with small vessel disease feel better after a stroke.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: The First Hospital of Jilin University (Academic / other)
• Locations: 1 site (Changchun, Jilin)
• Trial ID: NCT05914623 on ClinicalTrials.gov

What this trial studies

This study investigates how high-frequency repetitive transcranial magnetic stimulation (rTMS) affects cerebral autoregulation in patients diagnosed with cerebral small vessel disease (CSVD). It aims to determine if rTMS can enhance nerve cell excitability, improve blood supply in intracerebral arteries, and potentially reduce neurological impairments associated with stroke. Participants will receive either active rTMS or a sham treatment, and their responses will be monitored to assess the efficacy of the intervention.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-80 diagnosed with cerebral small vessel disease and recent small subcortical infarcts.

Not a fit: Patients with significant vascular stenosis, recent history of heart issues, or contraindications to transcranial magnetic stimulation will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve blood flow regulation in the brain and reduce neurological impairments for patients with cerebral small vessel disease.

How similar studies have performed: Previous studies have shown that repetitive transcranial magnetic stimulation can positively affect neurological outcomes, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

1. Age 18-80 years, regardless of gender;
2. Diagnosed with CSVD, and neuroimaging presented as recent small subcortical infarcts;
3. Initiated transcranial magnetic stimulation within 7 days of onset;
4. Subject or legal representative agreed to the treatment and signed the informed consent;

Exclusion Criteria:

1. Vascular stenosis \> 50% diagnosed by Transcranial Doppler (TCD) and carotid ultrasound;
2. Previous history of atrial fibrillation or myocardial infarction within 6 months;
3. Moyamoya disease or hereditary cerebral small vessel disease, such as CADASIL;
4. White matter hyperintensities (WMH) of non-vascular origin;
5. Severe hepatic and renal diseases, cancer or other major diseases related to integral medical and surgical procedures;
6. Patients with contraindications to transcranial magnetic stimulation, such as metal or electronic devices in the brain;
7. Pregnant or breastfeeding women;
8. The patients with disorders of consciousness, agitation or insufficient bilateral temporal bone windows for insonation who cannot cooperate to dynamic cerebral autoregulation monitoring;
9. Previous history of epilepsy or family history of epilepsy;
10. Previous treatment with transcranial magnetic stimulation or its equivalent;
11. Unwillingness to be followed up or poor adherence to treatment;
12. Those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment, or who have participated in this study;
13. Other conditions that the investigators deemed unsuitable for enrollment.

Where this trial is running

Changchun, Jilin

• The First Hospital of Jilin University — Changchun, Jilin, China (Recruiting)

Study contacts

• Study coordinator: Yi Yang, MD,PhD

Conditions Transcranial Magnetic Stimulation